71 results
8-K/A
EX-99.1
KA
Kineta Inc
3 Feb 21
Other Events
4:59pm
approval for its product candidates, its product candidates may not achieve broad market acceptance by physicians, patients, healthcare payors, or others … the medical community, including physicians, patients, and healthcare payors. If any of its product candidates are approved but do not achieve an adequate
8-K
EX-99.1
KA
Kineta Inc
3 Apr 23
Kineta to Present at 22nd Annual Needham Healthcare Conference
7:01am
Exhibit 99.1
Kineta to Present at 22nd Annual Needham Healthcare Conference
SEATTLE — (April 3, 2023) Kineta, Inc. (Nasdaq: KA), a clinical-stage … Iadonato, Ph.D., CEO will present at the 22nd Annual Needham Healthcare Conference, being held virtually from April 17-20, 2023. Company management
8-K
EX-99.1
KA
Kineta Inc
23 May 23
Kineta to Present at Jefferies Healthcare Conference
9:30am
Exhibit 99.1
Kineta to Present at Jefferies Healthcare Conference
SEATTLE — (May 23, 2023) Kineta, Inc. (Nasdaq: KA), a clinical-stage … , Ph.D., Chief Executive Officer at Kineta, will present at the Jefferies Healthcare Conference, being held in New York, NY from June 7-9, 2023. Company
8-K
EX-99.5
KA
Kineta Inc
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
participants, diversion of healthcare resources away from clinical trials, travel or quarantine policies that may be implemented, and other factors … until Kineta receives regulatory approval from the Medicines and Healthcare products Regulatory Agency or other required regulatory approval in other
8-K
KA
Kineta Inc
16 Aug 21
Yumanity Therapeutics Appoints Michael D. Wyzga as Chief Financial Officer and Announces Inducement Grants
7:21am
as Healthcare Investment Banking Vice President and previously served as a Healthcare Investment Banking Associate from June 2014 to August 2021. Prior … to that, he served as a Healthcare Corporate and Investment Banking Analyst at CitiGroup, Inc. from 2011 to 2013. Mr. Wyzga received a B.A. in Finance from
424B3
illv9cq3 fa
10 Nov 22
Prospectus supplement
4:21pm
8-K/A
EX-99.3
zi0 gji59i0
3 Feb 21
Other Events
4:59pm
8-K
EX-99.1
e8w3 vnfag8r
16 Aug 21
Yumanity Therapeutics Appoints Michael D. Wyzga as Chief Financial Officer and Announces Inducement Grants
7:21am
8-K
EX-99.6
pyrtnlznda7p89
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm